For example, the fusion of EphA2-targeting peptides and paclitaxel has been an active area of investigation [127,128,129,130], in addition to a fusion of gemcitabine and an EphA2 peptide targeted to pancreatic cancer [131]. Here, EPHA2 is linked to familial pancreatic carcinoma.